Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
-
Wood trimmed major recent winners, selling about $18 million of TWST along with smaller positions in TXG and CDNA.
-
RXRX has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.
-
Intellia is awaiting FDA review of its lead therapy for hereditary angioedema,